Deals of the Week Looks at Ultra-Orphan Drug Pricing
In the first half of 2013, two drugs for serious, ultra-rare diseases will have launched in the U.S. priced at $250,000 annually. One is encountering minimal resistance among payers; the other is expected to face a hard road. Plus a look at Celgene/Forma, Bayer/Conceptus, Soligenix/Intrexon; Regeneron/Sanofi and more.
You may also be interested in...
Gilead and Vertex appealed shareholder requests to disclose the processes behind pricing decisions for Sovaldi, Harvoni and Kalydeco, but SEC rules it does not constitute micromanagement of the companies.
Two of the world’s largest pharmaceutical companies are teaming up to develop a treatment for type 2 diabetes, but the drug will have plenty of competitors with a better market position by the time it faces regulatory approval.
Forma Therapeutics has signed its largest and most ambitious oncology drug-discovery and development collaboration to date, in the exciting but early-stage area of protein homeostasis. Its new partner Celgene is no stranger to making big bets on promising cancer companies.